AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 83 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $988,800 | -37.5% | 96,000 | 0.0% | 0.50% | -32.1% |
| Q2 2023 | $1,582,080 | +79.9% | 96,000 | 0.0% | 0.74% | +80.0% |
| Q1 2023 | $879,360 | +27.9% | 96,000 | 0.0% | 0.41% | +29.4% |
| Q4 2022 | $687,360 | +43.2% | 96,000 | 0.0% | 0.32% | +26.4% |
| Q3 2022 | $480,000 | +105.1% | 96,000 | 0.0% | 0.25% | +129.4% |
| Q2 2022 | $234,000 | -43.8% | 96,000 | +57.4% | 0.11% | -37.7% |
| Q1 2022 | $416,000 | -15.4% | 61,000 | 0.0% | 0.18% | -13.4% |
| Q4 2021 | $492,000 | -17.6% | 61,000 | 0.0% | 0.20% | -24.9% |
| Q3 2021 | $597,000 | +45.6% | 61,000 | 0.0% | 0.27% | +48.6% |
| Q2 2021 | $410,000 | -25.6% | 61,000 | 0.0% | 0.18% | -28.2% |
| Q1 2021 | $551,000 | +35.4% | 61,000 | 0.0% | 0.25% | +22.9% |
| Q4 2020 | $407,000 | +32.6% | 61,000 | 0.0% | 0.20% | +24.2% |
| Q3 2020 | $307,000 | – | 61,000 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
| Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
| JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
| ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
| FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
| KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
| Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
| Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
| HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |